Abstract:

Background: The prevalence of patent ductus arteriosus (PDA) is inversely proportional to gestational age and birth weight, and may lead to many premature morbidities and mortality. There are contradictory results regarding the fact that magnesium sulphate (MgSO4), that is used as tocolytic in premature labor, increases the frequency of PDA. In our study, we aimed to determine the effect of antenatal MgSO4 application on haemodynamically significant PDA (hsPDA) in very low birth weight (VLBW; <1500g) premature infants. Methods: We retrospectively evaluated the medical records of VLBW preterm infants with very low birth weight (VLBW; <1500g) between January 2013 and December 2016.The demographic and clinical characteristics of the infants were recorded. The preterms included in the study were divided into two groups as with hsPDA and without hsPDA. Demographic, clinical features and MgSO4 administration were compared between two groups. Results: A total of 602 VLBW infans were included. 257 (42.7%) infants had hsPDA, and 11 (1.8%) infants with hsPDA had PDA ligation due to being unresponsive to medical treatment. The rate of administration of antenatal MgSO4 in the hsPDA group was 61.8% (n = 159), and the rate of antenatal MgSO4 administration in the non-hsPDA group was found to be statistically significant (31.6%) (n = 109) (p <0.001). Conclusions: In our study, the rate of antenatal MgSO4 administration and premature morbidities were found to be higher in the hsPDA group than infants without hsPDA.   Keywords: Hemodynamically significant patent ductus arteriosus, premature, very low birth weight, magnesium sulfate

Keywords: